Intermittent progestin administration as part of hormone replacement therapy: long-term comparison between estradiol 1 mg combined with intermittent norgestimate and estradiol2 mg combined with constant norethisterone acetate

References

• Breckwoldt M, Keck C, Karck U. Benefits and risks of hormone replacement therapy (HRT). J Steroid Biochem Mol Biol 1995; 53: 205–8.
   Google Scholar
• Calaf i Alsina J. Benefits of hormone replacement therapy– –overview and update. Int J Fertil Womens Medical 1997; 42: 329–46.
   Google Scholar
• Samsioe G. Osteoporosis – an update. Acta Obstet Gynecol Scand 1997; 76: 189–99.
   Google Scholar
• Ettinger B, Genant HK, Steiger P, Madvig P. Low-dosage micronized 17β-estradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol 1992; 166: 47988.
   Google Scholar
• Calle EE, Miracle-McMahill HL, Thun MJ, Heath CWJ. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 1995; 87: 517–23.
   Google Scholar
• Beckmann CRB. Alzheimer’s disease: an estrogen link? Curr Opin Obstet Gynecol 1997; 9: 295–9.
   Google Scholar
• Rice MM, Graves AB, McCurry SM, Larson EB. Estrogen replacement therapy and cognitive function in postmenopausal women without dementia. Am J Med 1997; 103: 26S–35S.
   Google Scholar
• Whitehead MI, Townsend PT, Pryse-Davies J, Ryder TA, King RJB. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 1981; 305: 1599–605.
   Google Scholar
• Jick H, Watkins RN, Hunter JR, Dinan BJ, Madsen S, Rothman KJ et al. Replacement estrogens and endometrial cancer. N Engl J Med 1979; 300: 218–22.
   Google Scholar
• Gambrell RD Jr. Prevention of endometrial cancer with progestogens. Maturitas 1986; 8: 159–68.
   Google Scholar
• Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergstrom R, Lindgren A et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91: 1131–7.
   Google Scholar
• Hammond CB. Women’s concerns with hormone replacement therapy – compliance issues. Fertil Steril 1994; 62 (Suppl. 2): 157S–60S.
   Google Scholar
• Panay N, Studd J. Progestogen intolerance and compliance with hormone replacement therapy in menopausal women. Hum Reprod Update 1997; 3: 159–71.
   Google Scholar
• Casper RF. Regulation of estrogen/progestogen receptors in the endometrium. Int J Fertil Menopausal Stud 1996; 41: 16–21.
   Google Scholar
• Eckert RL, Katzenellenbogen BS. Human endometrial cells in primary tissue culture: modulation of the progesterone receptor level by natural and synthetic estrogens in vitro. J Clin Endocrinol Metab 1981; 52: 699–708.
   Google Scholar
• Clark JH, Hsueh AJ, Peck EJ Jr. Regulation of estrogen receptor replenishment by progesterone. Ann N Y Acad Sci 1977; 286: 161–79.
   Google Scholar
• Whitehead MI, Townsend PT, Pryse-Davies J, Ryder T, Lane G, Siddle NC et al. Effects of various types and dosages of progestogens on the postmenopausal endometrium. J Reprod Med 1982; 27: 539–48.
   Google Scholar
• Cameron ST, Critchley HO, Glasier AF, Williams AR,Baird DT. Continuous transdermal oestrogen and interrupted progestogen as a novel bleed-free regimen of hormone replacement therapy for postmenopausal women. Br J Obstet Gynaecol 1997; 104: 1184–90.
   Google Scholar
• Callantine MR, Martin PL, Bolding OT, Warner PO, Greaney MO Jr. Micronized 17β-estradiol for oral estrogen therapy in menopausal women. Obstet Gynecol 1975; 46: 37–41.
   Google Scholar
• Anderson FD. Selectivity and minimal androgenicity of norgestimate in monophasic and triphasic oral contraceptives. Acta Obstet Gynecol Scand 1992; 156: 15–21.
   Google Scholar
• Phillips A. The selectivity of a new progestin. Acta Obstet Gynecol Scand 1990; 152: 21–4.
   Google Scholar
• Ylikorkala O, Lim P Caubel P Effects on serum lipid profiles of continuous 17β-estradiol, intermittent norgestimate regimens versus continuous combined 17β-estradiol/norethisterone acetate hormone replacement therapy. Clin Ther 2000; 22: 622–36.
   Google Scholar
• Rozenberg S, Caubel P, Lim PC. Constant estrogen, intermittent progestogen vs. continuous combined hormone replacement therapy: tolerability and effect on vasomotor symptoms. Int J Gynecol Obst 2001; 72: 235–43.
   Google Scholar
• Johannisson E, Lim P. Endometrial effects of a 1-year pulsed progestogen, constant estrogen hormone replacement therapy regimen, Prefest™. Eur J Obstet Gynecol Reprod Biol 1999; 86: S17.
   Google Scholar
• Casper RF, Chapdelaine A. Estrogen and interrupted progestin: a new concept for menopausal hormone replacement therapy. Am J Obstet Gynecol 1993; 168: 1188–94.
   Google Scholar
• Samsioe G. Hormone replacement therapy: aspects of bleeding problems and compliance. Int J Fertil Menopausal Stud 1996; 41: 11–5.
   Google Scholar